ALL CONTENT

Tempus has built the world's largest library of clinical molecular data and an operating system to make that data accessible and useful, starting with cancer... Nature Biotechnology Study Reveals that Tempus' xT Platform Increases Cancer Patients' Personalized Therapeutic Opportunities Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing. A Pan-cancer Organoid Platform for Precision Medicine Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers. Validation of a Liquid Biopsy Assay with..

Primary location: Chicago United States